ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) announced its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Stock Up 3.6 %
Shares of EPIX traded up $0.16 during midday trading on Wednesday, reaching $4.62. 332 shares of the stock were exchanged, compared to its average volume of 94,939. ESSA Pharma has a 12-month low of $2.58 and a 12-month high of $11.67. The firm has a 50 day simple moving average of $5.26 and a 200-day simple moving average of $7.05. The company has a market cap of $204.94 million, a price-to-earnings ratio of -7.08 and a beta of 1.82.
Wall Street Analyst Weigh In
Separately, Oppenheimer restated an “outperform” rating and set a $17.00 price objective on shares of ESSA Pharma in a research report on Thursday, May 16th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Nuclear Power Giant’s Shares Jump on Raised Full-Year Guidance
- What Are the U.K. Market Holidays? How to Invest and Trade
- Airbnb Stock: Key Drivers Indicate Bright Future Despite Sell-Off
- Manufacturing Stocks Investing
- Amgen’s MariTide Weight Loss Potential: Stock Outlook
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
